NZ503432A - Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function - Google Patents
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase functionInfo
- Publication number
- NZ503432A NZ503432A NZ503432A NZ50343298A NZ503432A NZ 503432 A NZ503432 A NZ 503432A NZ 503432 A NZ503432 A NZ 503432A NZ 50343298 A NZ50343298 A NZ 50343298A NZ 503432 A NZ503432 A NZ 503432A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- homocyclic
- formula
- heterocyclic ring
- hydrogen
- Prior art date
Links
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title abstract 2
- 102100030011 Endoribonuclease Human genes 0.000 title abstract 2
- 101710199605 Endoribonuclease Proteins 0.000 title abstract 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000002148 esters Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 4
- 125000004417 unsaturated alkyl group Chemical group 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 150000007942 carboxylates Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001174 sulfone group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6014597P | 1997-09-26 | 1997-09-26 | |
| PCT/US1998/019973 WO1999016438A1 (en) | 1997-09-26 | 1998-09-23 | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ503432A true NZ503432A (en) | 2002-11-26 |
Family
ID=22027657
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ503432A NZ503432A (en) | 1997-09-26 | 1998-09-23 | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| NZ517808A NZ517808A (en) | 1997-09-26 | 2002-03-15 | Method for identifying compounds that modulate serine/threonine protein kinase function |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ517808A NZ517808A (en) | 1997-09-26 | 2002-03-15 | Method for identifying compounds that modulate serine/threonine protein kinase function |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6093728A (enExample) |
| EP (1) | EP1017384B1 (enExample) |
| JP (1) | JP2001517699A (enExample) |
| KR (1) | KR100547929B1 (enExample) |
| CN (1) | CN1167420C (enExample) |
| AR (1) | AR017266A1 (enExample) |
| AT (1) | ATE281834T1 (enExample) |
| AU (1) | AU748849B2 (enExample) |
| BG (1) | BG64784B1 (enExample) |
| BR (1) | BR9812682A (enExample) |
| CA (1) | CA2305370C (enExample) |
| DE (1) | DE69827516T2 (enExample) |
| DK (1) | DK1017384T3 (enExample) |
| ES (1) | ES2230719T3 (enExample) |
| HU (1) | HUP0004024A3 (enExample) |
| IL (4) | IL158649A0 (enExample) |
| NO (1) | NO325663B1 (enExample) |
| NZ (2) | NZ503432A (enExample) |
| PL (1) | PL191618B1 (enExample) |
| PT (1) | PT1017384E (enExample) |
| RU (1) | RU2230553C2 (enExample) |
| SK (1) | SK285357B6 (enExample) |
| TR (1) | TR200001546T2 (enExample) |
| TW (1) | TW581815B (enExample) |
| UA (1) | UA72448C2 (enExample) |
| WO (1) | WO1999016438A1 (enExample) |
| ZA (1) | ZA988797B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060142236A1 (en) * | 1994-05-31 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
| BR0208010A (pt) * | 2001-03-12 | 2004-12-21 | Avanir Pharmaceuticals | Composto de benzimidazol para modulação de ige e inibição de proliferação celular |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| WO2005013950A2 (en) * | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| EP1962892A4 (en) * | 2005-11-22 | 2011-10-12 | Univ South Florida | INHIBITION OF CELL PROLIFERATION |
| EP2013207B1 (en) | 2006-04-26 | 2012-04-25 | Cancer Research Technology Limited | Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
| ES2627352T3 (es) * | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| EP2839839B1 (en) * | 2007-02-28 | 2018-01-17 | Yeda Research And Development Company Limited | Nuclear targeting sequences |
| JP5352476B2 (ja) | 2007-06-05 | 2013-11-27 | 武田薬品工業株式会社 | キナーゼ阻害剤としての二環式複素環化合物 |
| JP5270553B2 (ja) | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2184285B1 (en) * | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010025448A2 (en) * | 2008-08-29 | 2010-03-04 | University Of South Florida | Inhibition of cell proliferation |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| EP2399921B1 (en) | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| NZ599549A (en) | 2009-10-26 | 2013-11-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| DK2531502T3 (da) | 2010-02-01 | 2014-05-19 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi |
| CN103998036B (zh) | 2011-10-19 | 2017-05-31 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
| BR112014013332B1 (pt) | 2011-12-02 | 2022-09-06 | Signal Pharmaceuticals, Llc | Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso |
| CN104271159B (zh) | 2012-02-24 | 2017-11-28 | 西格诺药品有限公司 | 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| WO2014145852A2 (en) * | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| MY189663A (en) | 2013-04-17 | 2022-02-23 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| EP3549940A1 (en) | 2013-04-17 | 2019-10-09 | Signal Pharmaceuticals, LLC | Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| EP3046929B1 (en) | 2013-09-17 | 2019-01-16 | Yeda Research and Development Co., Ltd. | Erk-derived peptides and uses thereof |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2016010886A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| ES2749103T3 (es) | 2014-09-12 | 2020-03-19 | Knopp Biosciences Llc | Benzoimidazol-1,2-ilamidas como activadores del canal Kv7 |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3590045A (en) * | 1969-09-25 | 1971-06-29 | Smith Kline French Lab | Certain substituted imidazo (4,5-b)pyridines |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| SE422799B (sv) | 1975-05-28 | 1982-03-29 | Merck & Co Inc | Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner |
| ES473201A1 (es) * | 1977-09-26 | 1979-03-16 | Degussa | Procedimiento para la preparacion de 7-azabencimidazoles |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| ES2064101T3 (es) * | 1990-04-02 | 1995-01-16 | Pfizer | Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina. |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| DE69222637T2 (de) * | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| JPH06503095A (ja) * | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP0654024A1 (en) * | 1992-08-06 | 1995-05-24 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5582995A (en) | 1993-06-11 | 1996-12-10 | The General Hospital Corporation | Methods of screening for compounds which inhibit the direct binding of Ras to Raf |
| CN1048015C (zh) * | 1993-07-06 | 2000-01-05 | 美国辉瑞有限公司 | 双环四氢吡唑并吡啶类化合物 |
| US5645982A (en) * | 1993-08-19 | 1997-07-08 | Systemix, Inc. | Method for screening potential therapeutically effective antiviral agents |
| GB9501567D0 (en) * | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
-
1998
- 1998-09-23 RU RU2000110736/15A patent/RU2230553C2/ru not_active IP Right Cessation
- 1998-09-23 PL PL339744A patent/PL191618B1/pl not_active IP Right Cessation
- 1998-09-23 US US09/160,212 patent/US6093728A/en not_active Expired - Fee Related
- 1998-09-23 IL IL15864998A patent/IL158649A0/xx not_active IP Right Cessation
- 1998-09-23 ES ES98949464T patent/ES2230719T3/es not_active Expired - Lifetime
- 1998-09-23 SK SK415-2000A patent/SK285357B6/sk unknown
- 1998-09-23 TR TR2000/01546T patent/TR200001546T2/xx unknown
- 1998-09-23 DK DK98949464T patent/DK1017384T3/da active
- 1998-09-23 AT AT98949464T patent/ATE281834T1/de not_active IP Right Cessation
- 1998-09-23 AU AU95781/98A patent/AU748849B2/en not_active Ceased
- 1998-09-23 JP JP2000513574A patent/JP2001517699A/ja not_active Withdrawn
- 1998-09-23 HU HU0004024A patent/HUP0004024A3/hu unknown
- 1998-09-23 WO PCT/US1998/019973 patent/WO1999016438A1/en not_active Ceased
- 1998-09-23 BR BR9812682-2A patent/BR9812682A/pt not_active Application Discontinuation
- 1998-09-23 EP EP98949464A patent/EP1017384B1/en not_active Expired - Lifetime
- 1998-09-23 CA CA002305370A patent/CA2305370C/en not_active Expired - Fee Related
- 1998-09-23 PT PT98949464T patent/PT1017384E/pt unknown
- 1998-09-23 DE DE69827516T patent/DE69827516T2/de not_active Expired - Fee Related
- 1998-09-23 IL IL13510998A patent/IL135109A0/xx not_active IP Right Cessation
- 1998-09-23 KR KR1020007003192A patent/KR100547929B1/ko not_active Expired - Fee Related
- 1998-09-23 NZ NZ503432A patent/NZ503432A/xx unknown
- 1998-09-23 CN CNB988107538A patent/CN1167420C/zh not_active Expired - Fee Related
- 1998-09-23 UA UA2000042349A patent/UA72448C2/uk unknown
- 1998-09-25 TW TW087115979A patent/TW581815B/zh not_active IP Right Cessation
- 1998-09-25 AR ARP980104793A patent/AR017266A1/es unknown
- 1998-09-25 ZA ZA9808797A patent/ZA988797B/xx unknown
-
2000
- 2000-03-15 IL IL135109A patent/IL135109A/en unknown
- 2000-03-24 NO NO20001555A patent/NO325663B1/no unknown
- 2000-04-19 BG BG104356A patent/BG64784B1/bg unknown
-
2002
- 2002-03-15 NZ NZ517808A patent/NZ517808A/en unknown
- 2002-11-15 US US10/294,802 patent/US6855723B2/en not_active Expired - Fee Related
-
2003
- 2003-10-29 IL IL158649A patent/IL158649A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| MY127881A (en) | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | |
| DE69411625D1 (de) | Benzofuranyl- und Thiophenylalkancarbonsäurederivate | |
| ATE211139T1 (de) | Tetrahydroimidazopyridoindoldione als cgmp spezifische pde hemmer | |
| CO5280078A1 (es) | Compuestos | |
| DK0738270T3 (da) | Dihydropyrazolopyrroler | |
| DE69907977D1 (de) | Pyrrolobenzodiazepine | |
| KR100263496B1 (ko) | 탁솔 유도체 및 이의 제조방법 | |
| DE59009074D1 (de) | Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus. | |
| NO149888C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-substituerte-2`-hydroksyl-6,7-benzomorfaner og syreaddisjonssalter derav | |
| AR002711A1 (es) | Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto. | |
| NO152047C (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksom 5-(paradeuterofenyl)-5-fenylhydantoin | |
| AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| ATE330958T1 (de) | Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate | |
| DK1204658T3 (da) | Benzofurylpiperazin-serotoninagonister | |
| ATE259813T1 (de) | Triazolopyrimidinderivate | |
| ES543837A0 (es) | Acidos 1-ciclopropil-6-fluor-1,4-dihidro-4-oxo-7-(3-oxo-1- piperazinil)-3-quinolin-carboxilicos | |
| FI953566A0 (fi) | Tahdospironia tai sen analogeja sisältäviä koostumuksia | |
| HRP20010885B1 (en) | Ethanesulfonyl-piperidine derivatives | |
| BG106520A (en) | Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity | |
| AU7935887A (en) | Therapeutic agent for the treatment of peptic ulcer disease | |
| DK0469837T3 (da) | Anvendelse af en forbindelse til fremstilling af et lægemiddel til sænkning af blodets urinsyreindhold | |
| ES476837A1 (es) | Procedimientos de preparar derivados pirimidinicos condensa-dos con cabeza de puente de nitrogeno. | |
| JPS5536454A (en) | Novel immunosuppressive agent | |
| NZ275620A (en) | 3-optionally substituted phenyl or naphthyl-1,2,4-triazole derivatives; pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ZENTARIS AG, DE Free format text: OLD OWNER(S): ASTA MEDICA AKTIENGESELLSCHAFT |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |